|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18 Pt 1
|
|
pubmed:dateCreated |
2007-9-18
|
|
pubmed:abstractText |
Recent studies showed that Fas ligand (FasL) induced apoptosis in tumor cells and suppressed the immune response in several types of tumors. However, the toxicity of FasL limited further administration. This study delivered FasL in prostate cancer cells using an improved prostate-restricted replicative adenovirus (PRRA), thereby improving the antitumor effect while decreasing systemic toxicity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5463-73
|
|
pubmed:meshHeading |
pubmed-meshheading:17875776-Adenoviridae,
pubmed-meshheading:17875776-Androgens,
pubmed-meshheading:17875776-Animals,
pubmed-meshheading:17875776-Antigens, Surface,
pubmed-meshheading:17875776-Apoptosis,
pubmed-meshheading:17875776-Cytoplasmic Vesicles,
pubmed-meshheading:17875776-Fas Ligand Protein,
pubmed-meshheading:17875776-Gene Therapy,
pubmed-meshheading:17875776-Genetic Vectors,
pubmed-meshheading:17875776-Glutamate Carboxypeptidase II,
pubmed-meshheading:17875776-Humans,
pubmed-meshheading:17875776-Male,
pubmed-meshheading:17875776-Mice,
pubmed-meshheading:17875776-Prostate,
pubmed-meshheading:17875776-Prostate-Specific Antigen,
pubmed-meshheading:17875776-Prostatic Neoplasms,
pubmed-meshheading:17875776-Virus Replication,
pubmed-meshheading:17875776-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
|
|
pubmed:affiliation |
Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA..
|
|
pubmed:publicationType |
Journal Article
|
